n(g),n(g')-dimethyl-l-arginine has been researched along with Dyslipidemias in 12 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since co-administration of ezetimibe, a specific inhibitor of cholesterol absorption into the intestine, has been shown to augment lipid-lowering effects of statins, ezetimibe plus statins is a novel therapeutic strategy for the treatment of dyslipidemia in high-risk patients." | 9.14 | Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. ( Fujiwara, N; Fukami, K; Kawagoe, Y; Nakamura, T; Okuda, S; Sato, E; Suzuki, T; Ueda, S; Ueda, Y; Yamagishi, S, 2010) |
| "In rats with dyslipidemia, atorvastatin therapy could reduce plasma level of ADMA and ADMA concentration in cardiac tissues, and these effects are associated with the dose of atorvastatin therapy." | 7.81 | Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats. ( Cai, A; Li, D; Liang, Q; Mai, W; Mai, Z; Qiu, R; Xu, R; Zeng, F; Zheng, D, 2015) |
| "The effects of eicosapentaenoic acid (EPA) on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure (CHF) patients with dyslipidemia remain unclear." | 7.80 | Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia. ( Atarashi, H; Kohashi, K; Kosugi, M; Kusama, Y; Morisawa, T; Nakagomi, A; Saiki, Y; Shimizu, W, 2014) |
| "The aim of this study was to investigate serum leptin, oxidized low density lipoprotein (ox-LDL) and asymmetric dimethylarginine (ADMA) levels and their interaction with dyslipidaemia in adolescents with polycystic ovary syndrome (PCOS)." | 7.74 | Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. ( Biberoğlu, G; Bideci, A; Camurdan, MO; Cinaz, P; Demirel, F; Hasanoğlu, A; Yesilkaya, E, 2007) |
| "Dyslipidemia was defined as total cholesterol levels ≥200 mg/dL and/or triglyceride level ≥150 mg/dL." | 5.40 | Comparison of plasma viscosity as a marker of endothelial dysfunction with nitric oxide and asymmetric dimethylarginine in subjects with dyslipidemia. ( Ercan, M; Firtina, S; Konukoglu, D, 2014) |
| "Since co-administration of ezetimibe, a specific inhibitor of cholesterol absorption into the intestine, has been shown to augment lipid-lowering effects of statins, ezetimibe plus statins is a novel therapeutic strategy for the treatment of dyslipidemia in high-risk patients." | 5.14 | Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. ( Fujiwara, N; Fukami, K; Kawagoe, Y; Nakamura, T; Okuda, S; Sato, E; Suzuki, T; Ueda, S; Ueda, Y; Yamagishi, S, 2010) |
| "In rats with dyslipidemia, atorvastatin therapy could reduce plasma level of ADMA and ADMA concentration in cardiac tissues, and these effects are associated with the dose of atorvastatin therapy." | 3.81 | Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats. ( Cai, A; Li, D; Liang, Q; Mai, W; Mai, Z; Qiu, R; Xu, R; Zeng, F; Zheng, D, 2015) |
| "The effects of eicosapentaenoic acid (EPA) on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure (CHF) patients with dyslipidemia remain unclear." | 3.80 | Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia. ( Atarashi, H; Kohashi, K; Kosugi, M; Kusama, Y; Morisawa, T; Nakagomi, A; Saiki, Y; Shimizu, W, 2014) |
| "The aim of this study was to investigate serum leptin, oxidized low density lipoprotein (ox-LDL) and asymmetric dimethylarginine (ADMA) levels and their interaction with dyslipidaemia in adolescents with polycystic ovary syndrome (PCOS)." | 3.74 | Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. ( Biberoğlu, G; Bideci, A; Camurdan, MO; Cinaz, P; Demirel, F; Hasanoğlu, A; Yesilkaya, E, 2007) |
| " However, poor polyphenol bioavailability and extensive metabolization restrict their applicability." | 2.72 | Increasing the Power of Polyphenols through Nanoencapsulation for Adjuvant Therapy against Cardiovascular Diseases. ( Baião, DDS; da Silva, DVT; Paschoalin, VMF; Trindade, LR, 2021) |
| "Dyslipidemia was defined as total cholesterol levels ≥200 mg/dL and/or triglyceride level ≥150 mg/dL." | 1.40 | Comparison of plasma viscosity as a marker of endothelial dysfunction with nitric oxide and asymmetric dimethylarginine in subjects with dyslipidemia. ( Ercan, M; Firtina, S; Konukoglu, D, 2014) |
| "Ezetimibe treatment (10mg/day) for 6 months significantly decreased circulating levels of LDL-cholesterol, triglycerides and ADMA, while it increased HDL-cholesterol levels." | 1.35 | Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. ( Adachi, H; Fujiwara, N; Kawagoe, Y; Nakamura, T; Okuda, S; Sato, E; Suzuki, T; Ueda, S; Ueda, Y; Yamagishi, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Trindade, LR | 1 |
| da Silva, DVT | 1 |
| Baião, DDS | 1 |
| Paschoalin, VMF | 1 |
| Venkatesh, R | 1 |
| Srinivasan, K | 1 |
| Singh, SA | 1 |
| Wielkoszyński, T | 1 |
| Zalejska-Fiolka, J | 1 |
| Strzelczyk, JK | 1 |
| Owczarek, AJ | 1 |
| Cholewka, A | 1 |
| Furmański, M | 1 |
| Stanek, A | 1 |
| Ercan, M | 1 |
| Firtina, S | 1 |
| Konukoglu, D | 1 |
| Kohashi, K | 1 |
| Nakagomi, A | 1 |
| Saiki, Y | 1 |
| Morisawa, T | 1 |
| Kosugi, M | 1 |
| Kusama, Y | 1 |
| Atarashi, H | 1 |
| Shimizu, W | 1 |
| Zheng, D | 1 |
| Liang, Q | 1 |
| Zeng, F | 1 |
| Mai, Z | 1 |
| Cai, A | 1 |
| Qiu, R | 1 |
| Xu, R | 1 |
| Li, D | 1 |
| Mai, W | 1 |
| Nakamura, T | 3 |
| Sato, E | 3 |
| Fujiwara, N | 3 |
| Kawagoe, Y | 3 |
| Ueda, Y | 3 |
| Suzuki, T | 3 |
| Ueda, S | 3 |
| Adachi, H | 2 |
| Okuda, S | 3 |
| Yamagishi, S | 3 |
| Yamada, S | 1 |
| Takeuchi, M | 1 |
| Fukami, K | 2 |
| Matsui, T | 1 |
| Nishiyama, Y | 1 |
| Ueda, M | 1 |
| Katsura, K | 1 |
| Otsuka, T | 1 |
| Abe, A | 1 |
| Nagayama, H | 1 |
| Katayama, Y | 1 |
| Demirel, F | 1 |
| Bideci, A | 1 |
| Cinaz, P | 1 |
| Camurdan, MO | 1 |
| Biberoğlu, G | 1 |
| Yesilkaya, E | 1 |
| Hasanoğlu, A | 1 |
| Schiffrin, EL | 1 |
| Lipman, ML | 1 |
| Mann, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Influence of Preoperative Hemodialysis or Intraoperative Modified Ultrafiltration on Postoperative Outcome for Patients With Severe Renal Dysfunction Undergoing Open Heart Surgery: Randomized, Controlled, Multicenter Clinical Trial[NCT00720967] | Phase 3 | 450 participants (Anticipated) | Interventional | 2008-11-30 | Not yet recruiting | ||
| Effect of Beraprost Sodium on Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy (BESTinDN Study)[NCT01796418] | 102 participants (Anticipated) | Interventional | 2013-03-31 | Recruiting | |||
| A Multicenter, Randomized Trial to Compare Xience and Vision Coronary Stents in the Same Multivessel Patient With Chronic Kidney Disease[NCT00818792] | Phase 2 | 215 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for n(g),n(g')-dimethyl-l-arginine and Dyslipidemias
| Article | Year |
|---|---|
Increasing the Power of Polyphenols through Nanoencapsulation for Adjuvant Therapy against Cardiovascular Diseases.
Topics: Antioxidant Response Elements; Antioxidants; Arginine; Cardiotonic Agents; Diabetes Mellitus; Drug C | 2021 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
Chronic kidney disease: effects on the cardiovascular system.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Atherosclerosis; Biomarker | 2007 |
1 trial available for n(g),n(g')-dimethyl-l-arginine and Dyslipidemias
| Article | Year |
|---|---|
Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Anticholesteremic Agents; Arginine; Azetidines; Cholesterol; Cho | 2010 |
9 other studies available for n(g),n(g')-dimethyl-l-arginine and Dyslipidemias
| Article | Year |
|---|---|
Effect of arginine:lysine and glycine:methionine intake ratios on dyslipidemia and selected biomarkers implicated in cardiovascular disease: A study with hypercholesterolemic rats.
Topics: Administration, Oral; Amino Acids; Animals; Arginine; Biomarkers; Body Weight; Cardiovascular Diseas | 2017 |
Oxysterols Increase Inflammation, Lipid Marker Levels and Reflect Accelerated Endothelial Dysfunction in Experimental Animals.
Topics: Animals; Arginine; Aryldialkylphosphatase; C-Reactive Protein; Cholesterol; Dyslipidemias; Homocyste | 2018 |
Comparison of plasma viscosity as a marker of endothelial dysfunction with nitric oxide and asymmetric dimethylarginine in subjects with dyslipidemia.
Topics: Adult; Aged; Arginine; Atherosclerosis; Biomarkers; Blood Viscosity; Dyslipidemias; Endothelium, Vas | 2014 |
Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia.
Topics: Aged; Arginine; Biomarkers; Chemokine CCL2; Chromatography, High Pressure Liquid; Chronic Disease; D | 2014 |
Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats.
Topics: Animals; Arginine; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Creatine Kinase; Dysl | 2015 |
Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner.
Topics: Adult; Arginine; Azetidines; Cholesterol; Dyslipidemias; Ezetimibe; Female; Humans; Kidney Failure, | 2009 |
Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.
Topics: Adult; Arginine; Cross-Sectional Studies; Dyslipidemias; Female; Glycation End Products, Advanced; H | 2009 |
Asymmetric dimethylarginine (ADMA) as a possible risk marker for ischemic stroke.
Topics: Age Factors; Aged; Arginine; Biomarkers; Blood Glucose; Brain Ischemia; Cholesterol, LDL; Dyslipidem | 2010 |
Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome.
Topics: Adolescent; Apolipoproteins B; Arginine; Biomarkers; Case-Control Studies; Cholesterol; Cholesterol, | 2007 |